Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Kamada (KMDA) stocks in Canada

Learn how to easily invest in Kamada stocks.

Kamada Ltd
+ $0.03 ( + 0.51%)

Kamada is a drug manufacturers-specialty & generic business based in the US. Kamada stocks (KMDA.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $5.72 – a decrease of 5.28% over the previous week. Kamada employs 408 staff and has a trailing 12-month revenue of around $103.7 million.

How to buy shares in Kamada

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – KMDA – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Kamada stock price (NASDAQ:KMDA)

Use our graph to track the performance of KMDA stocks over time.

Kamada shares at a glance

Information last updated 2022-01-24.
Latest market close$5.92
52-week range$5.11 - $8.16
50-day moving average $6.37
200-day moving average $5.84
Wall St. target price$11.00
PE ratio 68.6813
Dividend yield N/A (0%)
Earnings per share (TTM) $0.09

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get up to $5,000 cash back. Conditions apply. Offer ends March 1, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy Kamada stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Kamada price performance over time

Historical closes compared with the close of $5.92 from 2022-01-27

1 week (2022-01-21) -5.28%
1 month (2021-12-29) -10.98%
3 months (2021-10-29) 3.68%
6 months (2021-07-29) 9.23%
1 year (2021-01-29) -8.50%
2 years (2020-01-29) -10.03%
3 years (2019-01-29) 13.19%
5 years (2017-01-27) 6.05

Is Kamada under- or over-valued?

Valuing Kamada stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Kamada's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Kamada's P/E ratio

Kamada's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 69x. In other words, Kamada shares trade at around 69x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Kamada's PEG ratio

Kamada's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 8.75. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Kamada's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Kamada's EBITDA

Kamada's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $9.8 million.

The EBITDA is a measure of a Kamada's overall financial performance and is widely used to measure a its profitability.

Kamada financials

Revenue TTM $103.7 million
Operating margin TTM 5.74%
Gross profit TTM $47.6 million
Return on assets TTM 1.76%
Return on equity TTM 2.46%
Profit margin 4.25%
Book value $4.30
Market capitalisation $290.8 million

TTM: trailing 12 months

Kamada share dividends

We're not expecting Kamada to pay a dividend over the next 12 months.

Kamada share price volatility

Over the last 12 months, Kamada's shares have ranged in value from as little as $5.11 up to $8.16. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Kamada's is 0.2288. This would suggest that Kamada's shares are less volatile than average (for this exchange).

Kamada overview

Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. It operates in two segments, Proprietary Products and Distribution. The company offers Glassia for use in chronic augmentation and maintenance therapy in adults with emphysema due to congenital Alpha-1 Antitrypsin (AAT) deficiency. It also provides KamRAB for prophylaxis of rabies disease; KamRho (D) IM to treat prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes Bramitob to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; IVIG 5% for the treatment of various immunodeficiency-related conditions; AeroBika, an OPEP device; Varitect, a varicella zoster immunoglobulin; Zutectra and Hepatect CP for the prevention of hepatitis B virus; Megalotect, a CMV immunoglobulin; and RUCONEST for the treatment of acute angioedema attacks in adults with hereditary angioedema. Further, it distributes Heparin sodium injection to treat thrombo-embolic disorders; Albumin and Albumin 4% for maintenance of blood plasma; and coagulation factors comprising Factor VIII and Factor IX, as well as IXIARO vaccine.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site